Baclofen Sustained Release 30 mg | BACLOFINE SR 30

Baclofen Sustained Release 30 mg is a centrally acting muscle relaxant and GABA-B receptor agonist prescribed for the long-term management of muscle spasticity caused by neurological conditions including multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. Unlike the immediate-release formulation that requires dosing three times a day, the sustained-release 30mg tablet releases the drug gradually and consistently over the full 24-hour cycle — providing stable, uninterrupted muscle relaxation with just one tablet taken once daily. This significantly improves patient compliance, reduces the risk of side effects caused by peak plasma fluctuations, and delivers better day-long spasticity control. It is a Schedule H prescription-only medicine and must be used strictly under the supervision of a qualified neurologist or physician.

What Is Baclofen Sustained Release 30 mg?

Baclofen Sustained Release 30 mg is a modified-release oral tablet formulation of Baclofen — a centrally acting skeletal muscle relaxant that belongs to the GABA-B receptor agonist class of medicines. It is specifically engineered to deliver a controlled, steady release of 30mg of Baclofen into the bloodstream over a 24-hour period, maintaining consistent therapeutic drug levels without the peaks and troughs that are associated with the conventional immediate-release (IR) formulation.

Baclofen as a molecule has been clinically established for decades as one of the most effective and widely prescribed medicines for neurogenic muscle spasticity — abnormal, involuntary muscle stiffness and spasms that arise from damage or disease affecting the central nervous system rather than the muscles themselves. The sustained-release formulation represents a significant advancement in how Baclofen therapy is delivered — reducing the dosing frequency from three times daily to once daily, simplifying the patient's medication routine, and improving long-term therapeutic outcomes through more stable drug exposure throughout the day and night.

Steris Healthcare's BACLOFINE SR 30 is a clinically trusted formulation of Baclofen Sustained Release 30 mg, built on this sustained-release technology platform and designed for patients who need reliable, long-lasting neurological muscle relaxation as part of their ongoing neurological care.

How Does Baclofen Sustained Release 30 mg Work?

Baclofen Sustained Release 30 mg works through a well-understood and clinically validated mechanism that acts directly on the central nervous system — specifically at the level of the spinal cord — to reduce the abnormal nerve signals responsible for muscle spasticity.

GABA-B Receptor Agonism

Baclofen is a structural analogue of gamma-aminobutyric acid (GABA) — the brain's primary inhibitory neurotransmitter. It works by selectively binding to and activating GABA-B receptors located on the presynaptic terminals of motor neurons in the spinal cord. When these receptors are activated by Baclofen, they reduce the release of excitatory neurotransmitters — particularly glutamate and aspartate — that are responsible for triggering and sustaining excessive muscle contractions. By suppressing this excessive excitatory signalling at the spinal cord level, Baclofen directly reduces muscle tone, decreases the frequency and severity of muscle spasms, relieves pain associated with spasticity, and improves voluntary motor control and mobility in affected patients.

The Sustained Release Advantage

In the conventional immediate-release (IR) formulation, Baclofen reaches its peak plasma concentration rapidly after ingestion and then drops quickly — creating a cycle of high-effect periods followed by reduced-effect windows, which often causes side effects like drowsiness and dizziness at peak concentration while failing to control spasticity adequately during the trough periods.

The sustained-release 30 mg tablet eliminates this problem entirely. Its advanced matrix delivery technology releases Baclofen slowly and uniformly over 24 hours, maintaining steady therapeutic plasma levels throughout the entire day — providing consistent muscle relaxation without the abrupt fluctuations. Clinical studies published in Neurology India have confirmed that once-daily Baclofen SR is equivalent in spasticity control efficacy to three-times-daily IR dosing, with significantly better patient compliance and tolerability.

Therapeutic Uses of Baclofen Sustained Release 30 mg

Baclofen Sustained Release 30 mg is prescribed by neurologists, physiatrists, and physicians for the following clinically established indications:

Multiple Sclerosis (MS) Related Spasticity

Multiple sclerosis is the most common neurological condition for which Baclofen is prescribed. In MS, demyelination of nerve fibres in the spinal cord disrupts the normal regulation of muscle tone, leading to painful and debilitating spasticity. Baclofen SR 30 mg is a first-line pharmacological treatment for MS-related spasticity — reducing muscle stiffness, decreasing spasm frequency, relieving pain, and improving the patient's functional independence in daily activities such as walking, dressing, and personal hygiene.

Spinal Cord Injury (SCI) Related Spasticity

Spinal cord injuries — whether traumatic (from accidents or falls) or non-traumatic (from tumours or infections) — frequently cause severe neurogenic spasticity below the level of injury. Baclofen SR 30 mg provides reliable and long-lasting relief from this spasticity by suppressing the hyperexcitable spinal reflex arcs that develop below the injury site, helping patients maintain better posture, prevent contractures, and engage more effectively with physiotherapy and rehabilitation.

Cerebral Palsy

Children and adults with cerebral palsy often experience significant muscle stiffness and spasticity that impairs mobility and causes pain. Baclofen SR 30 mg — when dosed appropriately under specialist guidance — reduces spastic muscle tone, making it easier for patients to perform physiotherapy exercises, improve gait patterns, and participate in daily activities with greater comfort and independence.

Traumatic Brain Injury (TBI)

Muscle spasticity is a common and often underappreciated complication of moderate to severe traumatic brain injury. Baclofen SR 30 mg helps manage this post-TBI spasticity by reducing abnormal muscle overactivity originating from disrupted supraspinal control, which in turn supports better rehabilitation outcomes and improved functional recovery.

Stroke-Related Spasticity

While Baclofen is not the first-line recommendation for pure stroke-related spasticity in all guidelines, it is used in certain clinical contexts — particularly where spinal cord spasticity components are involved — under the careful guidance of a neurologist or rehabilitation medicine specialist.

Dosage and Administration of Baclofen Sustained Release 30 mg

Baclofen Sustained Release 30 mg is taken once daily, orally, at the same time every day. The tablet must be swallowed whole with a full glass of water. It must never be chewed, crushed, split, or broken — doing so destroys the sustained-release matrix and releases the entire 30 mg dose at once, dramatically increasing the risk of adverse effects including severe drowsiness, muscle weakness, and respiratory depression.

The tablet can be taken with or without food, though taking it with a meal may reduce the likelihood of gastrointestinal discomfort in sensitive patients.

Standard Adult Dosing Protocol:

Baclofen therapy is always initiated at a low dose and titrated upward gradually to minimise side effects and allow the patient's body to adjust. Typical dosing progression follows this pattern:

Starting dose: Baclofen 10 mg or 20 mg IR three times daily (to establish tolerability), then transitioned to Baclofen SR 30 mg once daily as maintenance therapy. The maximum recommended daily oral dose of Baclofen is 80 mg per day across all formulations.

Dose adjustments are made based on the patient's spasticity severity, functional improvement, and tolerability — always under the treating neurologist or physician's supervision.

Never stop Baclofen abruptly. Sudden discontinuation of Baclofen — even the sustained-release formulation — can cause serious withdrawal effects including rebound spasticity, hallucinations, seizures, and in severe cases, a life-threatening withdrawal syndrome. Any dose reduction must be done gradually and only under strict medical supervision.

Common Side Effects of Baclofen Sustained Release 30 mg

The sustained-release formulation significantly reduces the incidence and severity of side effects compared to immediate-release Baclofen by maintaining stable plasma levels and avoiding sharp concentration peaks. However, some patients may still experience the following:

Commonly reported side effects include:

• Drowsiness and sedation — particularly during the initial weeks of therapy
• Dizziness or light-headedness
• Muscle weakness (hypotonia)
• Fatigue and general tiredness
• Nausea and mild gastrointestinal upset
• Headache
• Dry mouth
• Constipation

Less common but clinically significant side effects:

• Confusion or cognitive slowing — particularly in elderly patients
• Low blood pressure (hypotension)
• Urinary frequency or retention
• Mood changes or depression
• Sleep disturbances
• Elevated blood glucose in diabetic patients — physician monitoring recommended

If a patient experiences difficulty breathing, severe muscle weakness, sudden confusion, or loss of consciousness, immediate medical attention must be sought.

Important Precautions and Contraindications

Baclofen Sustained Release 30 mg is contraindicated in patients with known hypersensitivity to Baclofen or any tablet excipient. It is not indicated for the treatment of spasticity caused by stroke, Parkinson's disease, or rheumatic disorders — where the risk-benefit profile does not support its use.

Caution is required in patients with epilepsy, as Baclofen can lower the seizure threshold in some individuals. Regular seizure monitoring is recommended in patients with a known seizure history who are prescribed Baclofen SR.

Patients with peptic ulcer disease, gastrointestinal obstruction disorders, or significant renal impairment require careful dose adjustment and close clinical monitoring throughout therapy. In patients with renal impairment, Baclofen clearance is reduced — meaning even standard doses can accumulate to toxic levels without appropriate dose reduction.

Elderly patients are particularly susceptible to the sedative and hypotensive effects of Baclofen SR 30 mg and should always begin therapy at the lowest effective dose. Patients must be advised not to drive or operate heavy machinery until they know how Baclofen SR affects them individually.

This medicine must not be used during pregnancy unless the treating physician has determined that the clinical benefit clearly outweighs the potential risk to the foetus.

Choose Steris Healthcare for Baclofen Sustained Release 30 mg — BACLOFINE SR 30

When your patients need reliable, long-lasting muscle spasticity management, BACLOFINE SR 30 by Steris Healthcare delivers exactly what neurological care demands. Formulated with precision sustained-release technology, each tablet of BACLOFINE SR 30 provides consistent 24-hour GABA-B receptor activation — reducing spasms, improving mobility, and supporting better rehabilitation outcomes with just one tablet a day.

Manufactured under WHO-GMP, ISO 9001:2018 certified standards and backed by Steris Healthcare's unwavering commitment to formulation quality, API purity, and patient safety, BACLOFINE SR 30 is a trusted choice for neurologists, physiatrists, and rehabilitation specialists across India. Affordable pricing and pan-India availability mean that no patient's long-term neurological care is ever compromised by access or cost. That is the Steris Healthcare promise — quality that reaches every patient who needs it.

Frequently Asked Questions (FAQ):  

Q1. What is Baclofen Sustained Release 30 mg used for?

A: Baclofen SR 30 mg — a GABA-B agonist — treats muscle spasticity from MS, spinal cord injury, and cerebral palsy.

Q2. How is Baclofen Sustained Release 30 mg different from regular Baclofen?

A: SR releases slowly over 24 hours — once daily vs. three times daily for immediate release.

Q3. Can Baclofen SR 30mg tablet be cut or crushed?

A: No — it must be swallowed whole; crushing destroys the sustained-release mechanism completely.

Q4. What happens if I stop Baclofen SR 30 mg suddenly?

A: Abrupt stopping causes rebound spasticity, hallucinations and seizures — never stop suddenly.

Q5. Can Baclofen SR 30 mg cause drowsiness?

A: Yes — drowsiness is common initially; avoid driving until you know how it affects you.

Q6. How long does Baclofen Sustained Release 30 mg take to work?

A: Noticeable spasticity relief is usually seen within 1 to 2 weeks of consistent daily use.